---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-254153"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:45:57.028629+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Travere Therapeutics prices $125M public offering of 7.8M shares at $16.00/share

## Summary
- Priced 7,812,500 shares at $16.00 per share; gross proceeds of $125.0M.
- Net proceeds expected ~$117.0M after underwriting discounts and expenses.
- Underwriters have 30-day option to purchase up to 1,171,875 additional shares.
- Closing expected November 12, 2024; Jefferies and Leerink Partners are joint book-runners.
- Proceeds for general corporate purposes including commercialization and R&D.

## SEC filing metadata
- accession: 0001193125-24-254153
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/0001193125-24-254153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312524254153/d632981d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-254153
- JSON: https://secwatch.observer/filing/0001193125-24-254153.json
- Plain text: https://secwatch.observer/filing/0001193125-24-254153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.